

Thomas P Conrads

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9451616/publications.pdf>

Version: 2024-02-01

43
papers

1,922
citations

361045

20
h-index

253896

43
g-index

46
all docs

46
docs citations

46
times ranked

3064
citing authors

#	ARTICLE	IF	CITATIONS
1	Peptide ancestry informative markers in uterine neoplasms from women of European, African, and Asian ancestry. <i>IScience</i> , 2022, 25, 103665.	1.9	5
2	Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer. <i>Cancers</i> , 2022, 14, 1496.	1.7	6
3	New Views of Old Proteins: Clarifying the Enigmatic Proteome. <i>Molecular and Cellular Proteomics</i> , 2022, 21, 100254.	2.5	16
4	Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. <i>Gynecologic Oncology</i> , 2021, 160, 777-785.	0.6	21
5	Proteogenomic landscape of uterine leiomyomas from hereditary leiomyomatosis and renal cell cancer patients. <i>Scientific Reports</i> , 2021, 11, 9371.	1.6	9
6	Deacetylation as a receptor-regulated direct activation switch for pannexin channels. <i>Nature Communications</i> , 2021, 12, 4482.	5.8	12
7	ELMO1 signaling is a promoter of osteoclast function and bone loss. <i>Nature Communications</i> , 2021, 12, 4974.	5.8	16
8	Obesity and altered angiogenic-related gene expression in endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 163, 320-326.	0.6	5
9	Jupiter microtubule-associated homolog 1 (JPT1): A predictive and pharmacodynamic biomarker of metformin response in endometrial cancers. <i>Cancer Medicine</i> , 2020, 9, 1092-1103.	1.3	10
10	Standardization and harmonization of distributed multi-center proteotype analysis supporting precision medicine studies. <i>Nature Communications</i> , 2020, 11, 5248.	5.8	49
11	The impact of ultraviolet- and infrared-based laser microdissection technology on phosphoprotein detection in the laser microdissection-reverse phase protein array workflow. <i>Clinical Proteomics</i> , 2020, 17, 9.	1.1	9
12	Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival. <i>Gynecologic Oncology</i> , 2020, 157, 67-77.	0.6	17
13	Integration of proteomics with CT-based qualitative and radiomic features in high-grade serous ovarian cancer patients: an exploratory analysis. <i>European Radiology</i> , 2020, 30, 4306-4316.	2.3	25
14	Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. <i>Cell Reports</i> , 2020, 31, 107502.	2.9	69
15	Biomarker panel for early detection of endometrial cancer in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 472.e1-472.e10.	0.7	10
16	From Discovery to Practice and Survivorship: Building a National Real-World Data Learning Healthcare Framework for Military and Veteran Cancer Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 52-57.	2.3	18
17	A noncanonical role for the engulfment gene ELMO1 in neutrophils that promotes inflammatory arthritis. <i>Nature Immunology</i> , 2019, 20, 141-151.	7.0	30
18	Recent advances and opportunities in proteomic analyses of tumour heterogeneity. <i>Journal of Pathology</i> , 2018, 244, 628-637.	2.1	21

#	ARTICLE	IF	CITATIONS
19	Racial disparities in molecular subtypes of endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 149, 106-116.	0.6	58
20	Impact of age at diagnosis on racial disparities in endometrial cancer patients. <i>Gynecologic Oncology</i> , 2018, 149, 12-21.	0.6	28
21	Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line. <i>Human Cell</i> , 2017, 30, 226-236.	1.2	7
22	Quantitative Mass Spectrometry by Isotope Dilution and Multiple Reaction Monitoring (MRM). <i>Methods in Molecular Biology</i> , 2017, 1606, 313-332.	0.4	10
23	Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients. <i>Cancer</i> , 2017, 123, 4004-4012.	2.0	25
24	Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients. <i>Oncotarget</i> , 2017, 8, 15912-15923.	0.8	9
25	NUAK1 (ARK5) Is Associated with Poor Prognosis in Ovarian Cancer. <i>Frontiers in Oncology</i> , 2016, 6, 213.	1.3	32
26	The Obama Administration's Cancer Moonshot: A Call for Proteomics. <i>Clinical Cancer Research</i> , 2016, 22, 4556-4558.	3.2	14
27	Nestin: A biomarker of aggressive uterine cancers. <i>Gynecologic Oncology</i> , 2016, 140, 503-511.	0.6	5
28	Identification and functional characterization of a novel bipartite nuclear localization sequence in ARID1A. <i>Biochemical and Biophysical Research Communications</i> , 2016, 469, 114-119.	1.0	7
29	Proteomics of the Human Endometrial Glandular Epithelium and Stroma from the Proliferative and Secretory Phases of the Menstrual Cycle1. <i>Biology of Reproduction</i> , 2015, 92, 106.	1.2	33
30	Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells. <i>Gynecologic Oncology</i> , 2015, 136, 554-561.	0.6	84
31	Elevated AKAP12 in Paclitaxel-Resistant Serous Ovarian Cancer Cells Is Prognostic and Predictive of Poor Survival in Patients. <i>Journal of Proteome Research</i> , 2015, 14, 1900-1910.	1.8	41
32	The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer <i>in vivo</i> . <i>Oncotarget</i> , 2015, 6, 44289-44305.	0.8	202
33	Distinct profiles of oxidative stress-related and matrix proteins in adult bone and soft tissue osteosarcoma and desmoid tumors: A proteomics study. <i>Human Pathology</i> , 2013, 44, 725-733.	1.1	18
34	Mitochondrial Proteomic Analysis of Cisplatin Resistance in Ovarian Cancer. <i>Journal of Proteome Research</i> , 2012, 11, 4605-4614.	1.8	48
35	Differential Proteomic Analysis of Late-Stage and Recurrent Breast Cancer from Formalin-Fixed Paraffin-Embedded Tissues. <i>Journal of Proteome Research</i> , 2011, 10, 1323-1332.	1.8	38
36	Proteomic Analysis of Ovarian Cancer Proximal Fluids: Validation of Elevated Peroxiredoxin 1 in Patient Peripheral Circulation. <i>PLoS ONE</i> , 2011, 6, e25056.	1.1	37

#	ARTICLE	IF	CITATIONS
37	Proteomic analysis of stage I endometrial cancer tissue: Identification of proteins associated with oxidative processes and inflammation. <i>Gynecologic Oncology</i> , 2011, 121, 586-594.	0.6	36
38	Standardization of a Sample Preparation and Analytical Workflow for Proteomics of Archival Endometrial Cancer Tissue. <i>Journal of Proteome Research</i> , 2011, 10, 5264-5271.	1.8	35
39	Mass spectrometric quantification of asparagine synthetase in circulating leukemia cells from acute lymphoblastic leukemia patients. <i>Journal of Proteomics</i> , 2008, 71, 61-70.	1.2	18
40	Proteomic Analysis of Laser-Captured Paraffin-Embedded Tissues: A Molecular Portrait of Head and Neck Cancer Progression. <i>Clinical Cancer Research</i> , 2008, 14, 1002-1014.	3.2	179
41	Mass spectrometric analysis of formalin-fixed paraffin-embedded tissue: Unlocking the proteome within. <i>Proteomics</i> , 2006, 6, 4106-4114.	1.3	89
42	Proteomic Analysis of Formalin-fixed Prostate Cancer Tissue. <i>Molecular and Cellular Proteomics</i> , 2005, 4, 1741-1753.	2.5	251
43	Utility of Accurate Mass Tags for Proteome-Wide Protein Identification. <i>Analytical Chemistry</i> , 2000, 72, 3349-3354.	3.2	269